Irodalom:
1. Sherman M, Yurdaydin C, Simsek H, Silva M, Liaw YF, Rustgi VK, Sette H, Tsai N, Tenney DJ, Vaughan J,
Kreter B, Hindes R.: AI463026 Benefits of Entecavir for Hepatitis B Liver Disease (BEHoLD) Study
Group. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical,
and serology outcomes through 96 weeks. Hepatology. 2008 Jul;48(1):99-108.
2. Schiff E, Simsek H, Lee WM, Chao YC, Sette Jr H, Janssen HL, Han SH, Goodman Z, Yang J, Brett-Smith H,
Tamez R.: Efficacy and Safety of Entecavir in Patients With Chronic Hepatitis B and Advanced Hepatic
Fibrosis or Cirrhosis. Am J Gastroenterol. 2008; 103:2776-2783.
3. Leemans WF, Niesters HG, van der Eijk AA, Janssen HL, Schalm SW, de Man RA.: Selection of an
entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B
patient with preexistent lamivudine resistance: successful rescue therapy with tenofovir. Eur J Gastroenterol
Hepatol. 2008 Aug;20(8):773-7.
4. Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R,
Kaita K, Manns M, Kotzev I, Tchernev K, Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H,
Washington MK, Sorbel J, Anderson J, Snow-Lampart A, Mondou E, Quinn J, Rousseau F.: Tenofovir
Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B. N Engl J Med. 2008
Dec 4;359(23):2442-2455.
5. Matthews GV, Avihingsanon A, Lewin SR, Amin J, Rerknimitr R, Petcharapirat P, Marks P, Sasadeusz J,
Cooper DA, Bowden S, Locarnini S, Ruxrungtham K, Dore GJ.: A randomized trial of combination
hepatitis B therapy in HIV/HBV coinfected antiretroviral naive individuals in Thailand. Hepatology.
2008 Oct;48(4):1062-9.
6. Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, Chen Y, Heathcote EJ, Rasenack J, Bzowej N,
Naoumov NV, Di Bisceglie AM, Zeuzem S, Moon YM, Goodman Z, Chao G, Constance BF, Brown NA;
Globe Study Group.: Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med.
2007 Dec 20;357(25):2576-88.
7. Hou J, Yin YK, Xu D, Tan D, Niu J, Zhou X, Wang Y, Zhu L, He Y, Ren H, Wan M,Chen C, Wu S, Chen Y,
Xu J, Wang Q, Wei L, Chao G, Constance BF, Harb G, Brown NA, Jia J.: Telbivudine versus lamivudine
in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial.
Hepatology. 2008 Feb;47(2):447-54.
8. Chan HL, Heathcote EJ, Marcellin P, Lai CL, Cho M, Moon YM, Chao YC, Myers RP,Minuk GY,
Jeffers L, Sievert W, Bzowej N, Harb G, Kaiser R, Qiao XJ, Brown NA; 018 Study Group.: Treatment
of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann
Intern Med. 2007 Dec 4;147(11):745-54.
9. Lim SG, Leung N, Hann HW, Lau GK, Trepo C, Mommeja-Marin H, Moxham C, Sorbel J, Snow A,
Blum MR, Rousseau F, Marcellin P.: Clinical trial: a phase II, randomized study evaluating the safety,
pharmacokinetics and anti-viral activity of clevudine for 12 weeks in patients with chronic hepatitis B.
Aliment Pharmacol Ther. 2008 Jun;27(12):1282-92.
Gastro 2009.qxd 5/9/2009 1:42 PM Page 422
Gyógyszerek, therápia 423
10. Rossignol JF, Keeffe EB.: Thiazolides: a new class of drugs for the treatment of chronic hepatitis B and
C. Future Microbiol. 2008 Oct;3:539-45.
11. Korba BE, Montero AB, Farrar K, Gaye K, Mukerjee S, Ayers MS, Rossignol JF.: Nitazoxanide,
tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication.
Antiviral Res. 2008 Jan;77(1):56-63. Epub 2007 Sep 4.
12. Cross TJ, Antoniades CG, Harrison PM.: Current and future management of chronic hepatitis C infection.
Postgrad Med J. 2008 Apr;84(990):172-6.
13. Cholongitas E, Papatheodoridis GV.: Review article: novel therapeutic options for chronic hepatitis C.
Aliment Pharmacol Ther. 2008 May;27(10):866-84.
14. Stauber RE, Kessler HH.: Drugs in development for hepatitis C. Drugs. 2008;68(10):1347-59.
15. Rossignol JF, Kabil SM, El-Gohary Y, Elfert A, Keeffe EB.: Clinical trial: randomized, double-blind,
placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic
hepatitis C genotype 4. Aliment Pharmacol Ther. 2008 Sep 1;28(5):574-80.
16. Ferenci P, Laferl H, Scherzer TM, Gschwantler M, Maieron A, Brunner H, Stauber R, Bischof M, Bauer B,
Datz C, Löschenberger K, Formann E, Staufer K, Steindl-Munda P; Austrian Hepatitis Study Group.:
Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological
response. Gastroenterology. 2008 Aug;135(2):451-8.
17. Scotto G, Fazio V, Fornabaio C, Tartaglia A, Di Tullio R, Saracino A, Angarano G.: Early and sustained
virological response in non-responders with chronic hepatitis C: a randomized open-label study of
pegylated interferon-alpha-2a versus pegylated interferon-alpha-2b. Drugs. 2008;68(6):791-801.
18. Angelico M, Koehler-Horst B, Piccolo P, Angelico F, Gentile S, Francioso S, Tarquini P, Vecchia RD,
Ponti L, Pilleri G, Barlattani A, Grieco A, Soccorsi F, Guarascio P, Demelia L, Sorbello O, Rossi Z,
Forlini G, Zaru S, Bandiera F; SMIEC II Investigators.: Peginterferon alpha-2a and ribavirin versus
peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and
ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological
nonresponders: the SMIEC II trial in naive patients with chronic hepatitis C. Eur J Gastroenterol
Hepatol. 2008 Jul;20(7):680-7.
19. von Wagner M, Hofmann WP, Teuber G, Berg T, Goeser T, Spengler U, Hinrichsen H, Weidenbach H,
Gerken G, Manns M, Buggisch P, Herrmann E, Zeuzem S.: Placebo- controlled trial of 400 mg
amantadine combined with peginterferon alfa-2a and ribavirin for 48 weeks in chronic hepatitis C
virus-1 infection. Hepatology. 2008 Nov;48(5):1404-11.
20. Gelderblom HC, Zeuzem S, Weegink CJ, Forestier N, Mcnair L, Purdy S, Dijkgraaf MG, Jansen PL,
Reesink HW.: Inflammatory markers neopterin and alanine aminotransferase in HCV patients treated
with HCV NS3.4A protease inhibitor telaprevir (VX-950) and/or peginterferon alfa-2a. Scand J
Gastroenterol. 2008;43(9):1122-7.
21. Roberts SK, Cooksley G, Dore GJ, Robson R, Shaw D, Berns H, Hill G, Klumpp K, Najera I, Washington C.:
Robust antiviral activity of R1626, a novel nucleoside analog: a randomized, placebo-controlled study
in patients with chronic hepatitis C. Hepatology. 2008 Aug;48(2):398-406.
22. Pockros PJ, Nelson D, Godofsky E, Rodriguez-Torres M, Everson GT, Fried MW, Ghalib R, Harrison S,
Nyberg L, Shiffman ML, Najera I, Chan A, Hill G.: R1626 plus peginterferon Alfa-2a provides potent
suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin.
Hepatology. 2008 Aug;48(2):385-97.
23. Klade CS, Wedemeyer H, Berg T, Hinrichsen H, Cholewinska G, Zeuzem S, Blum H, Buschle M,
Jelovcan S, Buerger V, Tauber E, Frisch J, Manns MP.: Therapeutic vaccination of chronic hepatitis C
nonresponder patients with the peptide vaccine IC41. Gastroenterology. 2008 May;134(5):1385-95.
Epub 2008 Mar 4.
Gastro 2009.qxd 5/9/2009 1:42 PM Page 423
424 Gastro Update 2009
24. Jones J, Panaccione R.: Biologic therapy in Crohn’s disease: state of the art. Curr Opin Gastroenterol.
2008 Jul;24(4):475-81.
25. Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF.: Efficacy and safety
of tumor necrosis factor antagonists in Crohn’s disease: meta-analysis of placebo-controlled trials. Clin
Gastroenterol Hepatol. 2008 Jun;6(6):644-53.
26. Behm BW, Bickston SJ.: Tumor necrosis factor-alpha antibody for maintenance of remisszión in Crohn’s
disease. Cochrane Database Syst Rev. 2008 Jan 23;(1):CD006893.
27. Kaser A, Tilg H.: Novel therapeutic targets in the treatment of IBD. Expert Opin Ther Targets.
2008 May;12(5):553-63.
28. Bank U, Bohr UR, Reinhold D, Lendeckel U, Ansorge S, Malfertheiner P, Tager M.: Inflammatory
bowel diseases: multiple benefits from therapy with dipeptidyl- and alanyl-aminopeptidase inhibitors.
Front Biosci. 2008 May 1;13:3699-713.
29. Ruyssers NE, De Winter BY, De Man JG, Loukas A, Herman AG, Pelckmans PA, Moreels TG.: Worms
and the treatment of inflammatory bowel disease: are molecules the answer? Clin Dev Immunol.
2008;2008:567314.
30. Seow CH, Benchimol EI, Griffiths AM, Steinhart AH.: Type I interferons for induction of remisszión in
ulcerative colitis. Cochrane Database Syst Rev. 2008 Jul 16;(3):CD006790.
31. Brain O, Travis SP.: Therapy of ulcerative colitis: state of the art. Curr Opin Gastroenterol.
2008 Jul;24(4):469-74.
32. Baumgart DC, Macdonald JK, Feagan B.: Tacrolimus (FK506) for induction of remisszión in refractory
ulcerative colitis. Cochrane Database Syst Rev. 2008 Jul 16;(3):CD007216.
33. Yamamoto S, Nakase H, Mikami S, Inoue S, Yoshino T, Takeda Y, Kasahara K, Ueno S, Uza N, Kitamura H,
Tamaki H, Matsuura M, Inui K, Chiba T.: Long-term effect of tacrolimus therapy in patients with
refractory ulcerative colitis. Aliment Pharmacol Ther. 2008 Sep 1;28(5):589-97.
34. Lawrance IC, Copeland TS.: Rectal tacrolimus in the treatment of resistant ulcerative proctitis. Aliment
Pharmacol Ther. 2008 Nov 15;28(10):1214-20.
35. Lichtenstein GR, Kamm MA, Sandborn WJ, Lyne A, Joseph RE.: MMX mesalazine for the induction of
remisszión of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient
subpopulations. Aliment Pharmacol Ther. 2008 Jun 1;27(11):1094-102.
36. Sandborn WJ, Feagan BG, Fedorak RN, Scherl E, Fleisher MR, Katz S, Johanns J, Blank M, Rutgeerts P;
Ustekinumab Crohn’s Disease Study Group.:A randomized trial of Ustekinumab, a human interleukin-12/23
monoclonal antibody, in patients with moderate-to-severe Crohn’s disease. Gastroenterology.
2008 Oct;135(4):1130-41.
37. Lewis JD, Lichtenstein GR, Deren JJ, Sands BE, Hanauer SB, Katz JA, Lashner B, Present DH, Chuai S,
Ellenberg JH, Nessel L, Wu GD.: Rosiglitazone for Ulcerative Colitis Study Group. Rosiglitazone for
active ulcerative colitis: a randomized placebo-controlled trial. Gastroenterology. 2008 Mar;134(3):688-95.
38. Pastorelli L, Saibeni S, Spina L, Signorelli C, Celasco G, de Franchis R, Vecchi M.: Oral, colonic-release
low-molecular-weight heparin: an initial open study of Parnaparin-MMX for the treatment of mild-to-moderate
left-sided ulcerative colitis. Aliment Pharmacol Ther. 2008 Sep 1;28(5):581-8.
39. Vakil N, Laine L, Talley NJ, Zakko SF, Tack J, Chey WD, Kralstein J, Earnest DL, Ligozio G,
Cohard-Radice M.: Tegaserod treatment for dysmotility-like functional dyspepsia: results of two
randomized, controlled trials. Am J Gastroenterol. 2008 Aug;103(8):1906-19.
40. Mishima Y, Amano Y, Okita K, Takahashi Y, Moriyama N, Ishimura N, Furuta K, Ishihara S, Adachi K,
Kinoshita Y.: Efficacy of prokinetic agents in improving bowel preparation for colonoscopy. Digestion.
2008;77(3-4):166-72.
Gastro 2009.qxd 5/9/2009 1:42 PM Page 424
Gyógyszerek, therápia 425
41. Spiller RC, Meyers NL, Hickling RI.: Identification of patients with non-d, non-C irritable bowel syndrome
and treatment with renzapride: an exploratory, multicenter, randomized, double-blind, placebo-controlled
clinical trial. Dig Dis Sci. 2008 Dec;53(12):3191-200.
42. George AM, Meyers NL, Hickling RI.: Clinical trial: renzapride therapy for constipation-predominant
irritable bowel syndrome–multicentre, randomized, placebo-controlled, double-blind study in primary
healthcare setting. Aliment Pharmacol Ther. 2008 May;27(9):830-7.
43. Stevens JE, Russo A, Maddox AF, Rayner CK, Phillips L, Talley NJ, Giguere M, Horowitz M, Jones KL.:
Effect of itopride on gastric emptying in longstanding diabetes mellitus. Neurogastroenterol Motil.
2008 May;20(5):456-63.
44. Talley NJ, Tack J, Ptak T, Gupta R, Giguere M.: Itopride in functional dyspepsia: results of two phase
III multicentre, randomised, double-blind, placebo-controlled trials. Gut. 2008 Jun;57(6):740-6. Epub
2007 Oct 26.
45. Camilleri M, Kerstens R, Rykx A, Vandeplassche L.: A placebo-controlled trial of prucalopride for s
evere chronic constipation. N Engl J Med. 2008 May 29;358(22):2344-54.
46. Matsueda K, Harasawa S, Hongo M, Hiwatashi N, Sasaki D.: A phase II trial of the novel serotonin
type 3 receptor antagonist ramosetron in Japanese male and female patients with diarrhea-predominant
irritable bowel syndrome. Digestion. 2008;77(3-4):225-35.
47. Mangel AW, Bornstein JD, Hamm LR, Buda J, Wang J, Irish W, Urso D.: Clinical trial: asimadoline in
the treatment of patients with irritable bowel syndrome. Aliment Pharmacol Ther. 2008 Jul;28(2):239-49.
48. McNicol E, Boyce DB, Schumann R, Carr D.: Efficacy and safety of mu-opioid antagonists in the treatment
of opioid-induced bowel dysfunction: systematic review and meta-analysis of randomized controlled
trials. Pain Med. 2008 Sep;9(6):634-59.
49. Thomas J, Karver S, Cooney GA, Chamberlain BH, Watt CK, Slatkin NE, Stambler N, Kremer AB,
Israel RJ.: Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med. 2008
May 29;358(22):2332-43.
50. Webster L, Jansen JP, Peppin J, Lasko B, Irving G, Morlion B, Snidow J, Pierce A,Mortensen E, Kleoudis C,
Carter E.: Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the
treatment of opioid-induced bowel dysfunction: results from a randomized, double-blind,
placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain.
Pain. 2008 Jul 15;137(2):428-40.
51. Pelham RW, Nix LC, Chavira RE, Cleveland MV, Stetson P.: Clinical trial: single- and multiple-dose
pharmacokinetics of polyethylene glycol (PEG-3350) in healthy young and elderly subjects. Aliment
Pharmacol Ther. 2008 Jul;28(2):256-65.
52. Geyer M, Manrique I, Degen L, Beglinger C.: Effect of yacon (Smallanthus sonchifolius) on colonic
transit time in healthy volunteers. Digestion. 2008;78(1):30-3.
53. Wu KL, Rayner CK, Chuah SK, Changchien CS, Lu SN, Chiu YC, Chiu KW, Lee CM.: Effects of ginger
on gastric emptying and motility in healthy humans. Eur J Gastroenterol Hepatol. 2008 May;20(5):436-40.
54. Hunt RH, Armstrong D, Yaghoobi M, James C, Chen Y, Leonard J, Shin JM, Lee E, Tang-Liu D, Sachs G.:
Predictable prolonged suppression of gastric acidity with a novel proton pump inhibitor, AGN 201904-Z.
Aliment Pharmacol Ther. 2008 Jul;28(2):187-99.
55. Du Y, Li Z, Zhan X, Chen J, Gao J, Gong Y, Ren J, He L, Zhang Z, Guo X, Wu J, Tian Z, Shi R, Jiang B,
Fang D, Li Y.: Anti-inflammatory Effects of Rebamipide According to Helicobacter pylori Status in
Patients with Chronic Erosive Gastritis: A Randomized Sucralfate-Controlled Multicenter Trial in
China-STARS Study. Dig Dis Sci. 2008 Nov;53(11):2886-95.
56. Chitapanarux T, Praisontarangkul OA, Lertprasertsuke N.: An open-labeled study of rebamipide treatment
Gastro 2009.qxd 5/9/2009 1:42 PM Page 425
426 Gastro Update 2009
in chronic gastritis patients with dyspeptic symptoms refractory to proton pump inhibitors. Dig Dis Sci.
2008 Nov;53(11):2896-903.
57. Niwa Y, Nakamura M, Ohmiya N, Maeda O, Ando T, Itoh A, Hirooka Y, Goto H.: Efficacy of rebamipide
for diclofenac-induced small-intestinal mucosal injuries in healthy subjects: a prospective, randomized,
double-blinded, placebo-controlled, cross-over study. J Gastroenterol. 2008;43(4):270-6.
58. Jafri NS, Hornung CA, Howden CW.: Meta-analysis: sequential therapy appears superior to standard
therapy for Helicobacter pylori infection in patients naive to treatment. Ann Intern Med. 2008 Jun
17;148(12):923-31.
59. Malfertheiner P, Schultze V, Rosenkranz B, Kaufmann SH, Ulrichs T, Novicki D, Norelli F, Contorni M,
Peppoloni S, Berti D, Tornese D, Ganju J, Palla E, Rappuoli R, Scharschmidt BF, Del Giudice G.: Safety
and immunogenicity of an intramuscular Helicobacter pylori vaccine in noninfected volunteers: a phase I
study. Gastroenterology. 2008 Sep;135(3):787-95.
60. Hyogo H, Tazuma S, Arihiro K, Iwamoto K, Nabeshima Y, Inoue M, Ishitobi T, Nonaka M, Chayama K.:
Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. Metabolism.
2008 Dec;57(12):1711-8.
61. Merat S, Aduli M, Kazemi R, Sotoudeh M, Sedighi N, Sohrabi M, Malekzadeh R.: Liver histology
changes in nonalcoholic steatohepatitis after one year of treatment with probucol. Dig Dis Sci. 2008
Aug;53(8):2246-50.
62. Ratziu V, Giral P, Jacqueminet S, Charlotte F, Hartemann-Heurtier A, Serfaty L, Podevin P, Lacorte JM,
Bernhardt C, Bruckert E, Grimaldi A, Poynard T; LIDO Study Group.: Rosiglitazone for nonalcoholic
steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with
Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology. 2008 Jul;135(1):100-10.
63. Aithal GP, Thomas JA, Kaye PV, Lawson A, Ryder SD, Spendlove I, Austin AS, Freeman JG, Morgan L,
Webber J.: Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic
steatohepatitis. Gastroenterology. 2008 Oct;135(4):1176-84.
64. Loomba R, Wesley R, Pucino F, Liang TJ, Kleiner DE, Lavine JE.: Placebo in nonalcoholic steatohepatitis:
insight into natural history and implications for future clinical trials. Clin Gastroenterol Hepatol. 2008
Nov;6(11):1243-8.
65. Martín-Llahí M, Pépin MN, Guevara M, Díaz F, Torre A, Monescillo A, Soriano G,Terra C, Fábrega E,
Arroyo V, Rodés J, Gines P; TAHRS Investigators.: Terlipressin and albumin vs albumin in patients
with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology. 2008 May;
134(5):1352-9.
66. Sanyal AJ, Boyer T, Garcia-Tsao G, Regenstein F, Rossaro L, Appenrodt B, Blei A, Gülberg V, Sigal S,
Teuber P; Terlipressin Study Group.: A randomized, prospective, double-blind, placebo-controlled trial
of terlipressin for type 1 hepatorenal syndrome. Gastroenterology. 2008 May;134(5):1360-8
67. Silano M, Vincentini O, Iapello A, Mancini E, De Vincenzi M.: Antagonist peptides of the gliadin T-cell
stimulatory sequences: a therapeutic strategy for celiac disease. J Clin Gastroenterol. 2008 Sep;42
Suppl 3 Pt 2:S191-2.
68. Wang HH, Portincasa P, Mendez-Sanchez N, Uribe M, Wang DQ.: Effect of ezetimibe on the prevention
and dissolution of cholesterol gallstones. Gastroenterology. 2008 Jun;134(7):2101-10.
69. Kremer AE, Beuers U, Oude-Elferink RP, Pusl T.: Pathogenesis and treatment of pruritus in cholestasis.
Drugs. 2008;68(15):2163-82.
70. Lanza FL, Marathi UK, Anand BS, Lichtenberger LM.:Clinical trial: comparison of ibuprofen-phosphatidylcholine
and ibuprofen on the gastrointestinal safety and analgesic efficacy in osteoarthritic patients. Aliment
Pharmacol Ther. 2008 Aug 15;28(4):431-42.
Gastro 2009.qxd 5/9/2009 1:42 PM Page 426
Gyógyszerek, therápia 427
71. Chaptini LA, Janec EM, Seltzer G, Peikin S, Elfant AB.: Sublingual hyoscyamine spray as premedication
for colonoscopy: a randomized double-blinded placebo-controlled trial. Am J Surg. 2008 Jul;196(1):51-5.
72. Purkayastha S, Tilney HS, Darzi AW, Tekkis PP.: Meta-analysis of randomized studies evaluating chewing
gum to enhance postoperative recovery following colectomy. Arch Surg. 2008 Aug;143(8):788-93.
